<div id="readability-page-1"><p>Pacer Advisors Inc. lessened its stake in shares of  Amgen Inc. (NASDAQ:AMGN - Free Report) by 8.8% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,613,121 shares of the medical research company's stock after selling 155,180 shares during the quarter. Amgen makes up  approximately  1.1% of Pacer Advisors Inc.'s portfolio, making the stock its 9th biggest position. Pacer Advisors Inc. owned 0.30% of Amgen worth $455,223,000 at the end of the most recent reporting period.</p><ul><li>3 Healthcare Giants Just Raised Dividends—Here’s Who Pays the Most</li></ul><p>Other hedge funds also recently made changes to their positions in the company. Fairvoy Private Wealth LLC boosted its position in  Amgen by 1.1% during the 2nd quarter. Fairvoy Private Wealth LLC now owns 3,171 shares of the medical research company's stock valued at $885,000 after buying an additional 35 shares during the period.  Nicholson Wealth Management Group LLC raised its stake in shares of  Amgen by 0.6% during the second quarter. Nicholson Wealth Management Group LLC now owns 5,918 shares of the medical research company's stock valued at $1,652,000 after acquiring an additional 35 shares during the last quarter.  Crumly &amp; Associates Inc. boosted its holdings in shares of  Amgen by 3.2% during the second quarter. Crumly &amp; Associates Inc. now owns 1,146 shares of the medical research company's stock worth $320,000 after purchasing an additional 36 shares during the period.  Maryland Capital Advisors Inc. grew its stake in shares of  Amgen by 5.2% in the second quarter. Maryland Capital Advisors Inc. now owns 732 shares of the medical research company's stock worth $204,000 after purchasing an additional 36 shares during the last quarter.  Finally, Lion Street Advisors LLC increased its holdings in  Amgen by 1.3% during the 2nd quarter. Lion Street Advisors LLC now owns 2,773 shares of the medical research company's stock valued at $774,000 after purchasing an additional 36 shares during the period. 76.50% of the stock is owned by hedge funds and other institutional investors. </p><h2>Insider Activity</h2><p>In other news, SVP Rachna Khosla sold 890 shares of the business's stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total value of $299,253.60. Following the sale, the senior vice president directly owned 7,082 shares of the company's stock, valued at $2,381,251.68. The trade was a 11.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Murdo Gordon sold 6,879 shares of the company's stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the completion of the sale, the executive vice president owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 10,908 shares of company stock worth $3,674,966. Insiders own  0.76% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><ul><li>5 Healthcare Names to Watch as Sector Rotation Is in Full Swing</li></ul><p>Several research firms have weighed in on AMGN. Truist Financial began coverage on Amgen in a report on Monday, November 24th. They issued a &#34;hold&#34; rating and a $318.00 price objective for the company. Bank of America raised their price target on Amgen from $261.00 to $272.00 and gave the stock an &#34;underperform&#34; rating in a research note on Friday, September 26th. The Goldman Sachs Group  reissued a &#34;buy&#34; rating on shares of Amgen in a research report on Tuesday, November 25th. Wells Fargo &amp; Company raised their target price on shares of Amgen from $300.00 to $325.00 and gave the stock an &#34;equal weight&#34; rating in a research report on Wednesday, December 10th. Finally, Piper Sandler lifted their target price on shares of Amgen from $342.00 to $381.00 and gave the company an &#34;overweight&#34; rating in a research note on Friday, November 14th. One analyst  has rated the stock with a Strong Buy rating, ten have assigned  a Buy rating, ten have assigned  a Hold rating and one  has assigned  a Sell rating to the company's stock. According to MarketBeat, Amgen presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $332.85.</p><p><b>Check Out Our Latest Report on Amgen</b></p><h2>Amgen Stock Performance</h2><ul><li>Amgen Stock: New All-Time Highs Ahead After Earnings Beat</li></ul><p>Shares of Amgen stock opened at $332.50 on Friday. The company has a current ratio of 1.28, a quick ratio of 0.99 and a debt-to-equity ratio of 5.45. The firm has a market capitalization of $179.04 billion, a P/E ratio of 25.70, a P/E/G ratio of 3.10 and a beta of 0.45. The business has a fifty day simple moving average of $322.29 and a two-hundred day simple moving average of $301.33. Amgen Inc. has a 12 month low of $257.05 and a 12 month high of $346.38. </p><p>Amgen (NASDAQ:AMGN - Get Free Report) last released its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, topping analysts' consensus estimates of $5.01 by $0.63. The firm had revenue of $9.56 billion for the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a net margin of 19.47% and a return on equity of 162.59%. The company's revenue was up 12.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS.  On average, equities analysts forecast that  Amgen Inc. will post 20.62 earnings per share for the current fiscal year. </p><h2>Amgen Increases Dividend</h2><p>The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Shareholders of record on Friday, February 13th will be paid a dividend of $2.52 per share. This is a positive change from Amgen's previous quarterly dividend of $2.38. This represents a $10.08 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Friday, February 13th. Amgen's payout ratio is 73.57%. </p><h2>Amgen Profile</h2> (Free Report)<p>Amgen Inc <span>NASDAQ: AMGN<span></span></span> is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.  </p><p>Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.</p><h2>Read More</h2><ul><li>Five stocks we like better than Amgen</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Washington prepares for war</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>The McDonald's Secret</li></ul><p><strong>Want to see what other hedge funds are holding AMGN?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU1HTg"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Amgen Right Now?</h2><p>Before you consider Amgen, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amgen wasn't on the list.</p><p>While Amgen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

AMGN

<p>Pacer Advisors Inc. reduced its stake in Amgen Inc. by 8.8% in Q3, now holding 1,613,121 shares. Amgen represents 1.1% of Pacer's portfolio. Other firms adjusted their Amgen holdings in Q2. Insiders sold 10,908 shares worth $3.67 million. Analysts have mixed ratings on Amgen, with a consensus "Moderate Buy" and a price target of $332.85. Amgen's stock opened at $332.50.</p>

Amgen Inc. $AMGN Stake Reduced by Pacer Advisors Inc.